Clinical experience with daptomycin for the treatment of patients with documented gram-positive septic arthritis

Annals of Pharmacotherapy

Volumn 42, Issue 2, 2008, Pages 213-217

  Forrest, Graeme N ^a   Donovan, Brian J ^b   Lamp, Kenneth C ^b   Friedrich, Lawrence V ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b CUBIST PHARMACEUTICALS INC   (United States)

Author keywords

Daptomycin; Septic arthritis; Staphylococcus aureus

Indexed keywords

DAPTOMYCIN; RIFAMPICIN;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL ARTHRITIS; BACTERIUM CULTURE; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; GRAM POSITIVE BACTERIUM; HOSPITAL ADMISSION; HOSPITAL CARE; HUMAN; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; OUTPATIENT CARE; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; TREATMENT DURATION; TREATMENT OUTCOME;

ARTHRITIS, INFECTIOUS; DAPTOMYCIN; FEMALE; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MALE; MIDDLE AGED; REGISTRIES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 39049148185     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1K535     Document Type: Article

References (20)

1. Ross JJ. Septic arthritis. Infect Dis Clin North Am 2005;19:799-817.
2. Ross JJ, Saltzman CL, Carling P, et al. Pneumococcal septic arthritis: review of 190 cases. Clin Infect Dis 2003;36:319-27.
3. Dubost JJ, Soubrier M, De Champs C, Ristori JM, Bussiere JL, Sauvezie B. No changes in the distribution of organisms responsible for septic arthritis over a 20 year period. Ann Rheum Dis 2002;61:267-9.
4. Lamas C, Boia M, Eykyn SJ. Osteoarticular infections complicating infective endocarditis: a study of 30 cases between 1969 and 2002 in a tertiary referral centre. Scand J Infect Dis 2006;38:433-40.
5. Smith JW, Chalupa P, Hasan MS. Infectious arthritis: clinical features, laboratory findings and treatment. Clin Microbiol Infect 2006;12:309-14.
6. Cooper C, Cawley MID. Bacterial arthritis in an English health district: a 10 year review. Ann Rheum Dis 1986;45:458-63.
7. Lidgren L. Orthopedic infections in patients with rheumatoid arthritis. Scand J Rheumatol 1973;2:92-6.
8. Kaandorp CJE, Dinant HJ, van de Laar MAFJ, Moens HJ, Prins AP, Dijkmans BA. Incidence and sources of native and prosthetic joint infection: a community based prospective survey. Ann Rheum Dis 1997;56:470-5.
9. Kaandorp CJ, Van Schaardenburg D, Krijnen P, Habbema JD, van de Laar MA. Risk factors for septic arthritis in patients with joint disease - a prospective study. Arthritis Rheum 1995;38:1819-25.
10. Weston V, Coakley G. Guideline for the management of the hot swollen joint in adults with a particular focus on septic arthritis. J Antimicrob Chemother 2006;58:492-3.
11. Mathews C, Field M, Jones A, et al. Guidelines for the management of the hot swollen joint in adults. Rheumatology (Oxford) 2006;45:1039-41.
12. Stengel D, Bauwens K, Sehouli J, Ekkernkamp A, Porzsolt F. Systematic review and meta-analysis of antibiotic therapy for bone and joint infections. Lancet Infect Dis 2001;1:175-88.
13. Moise PA, Forrest A, Birmingham MC, Schentag JJ. The efficacy and safety of linezolid as treatment for Staphylococcus aureus infections in compassionate use patients who are intolerant of, or who have failed to respond to, vancomycin. J Antimicrob Chemother 2002;50:1017-26.
14. Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004;38:1673-81.
15. Fowler VG, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 2006;355:653-65.
16. Lalani T, Boucher HW, Cosgrove SE, et al. Outcomes with daptomycin versus standard therapy for osteoarticular infections associated with Staphylococcus aureus bacteraemia. J Antimicrob Chemother 2008;61:177-82.
17. Segreti JA, Crank CW, Finney MS. Daptomycin for the treatment of Gram-positive bacteremia and infective endocarditis: a retrospective case series of 31 patients. Pharmacotherapy 2006;26:347-52.
18. Finney MS, Crank CW, Segreti MS. Use of daptomycin to treat drug-resistant Gram-positive bone and joint infections. Curr Med Res Opin 2005;12:1923-6.
19. Rolston KVI, Segreti J, Lamp KC, Friedrich LV. Cubicin outcomes registry and experience (CORE) methodology. Am J Med 2007;120(10A):S4-S5.
20. Cubicin (daptomycin) prescribing information. Lexington, MA: Cubist Pharmaceuticals, Inc., October 2007.